Welcome back to Baby Breakerdom! This week we find one company playing tag, a strange reversal in the biotech world, and chaperones for your genes.

This week's top story comes from the fast-paced world of RFID, otherwise known as radio frequency identification. Thursday brought news of potential Baby Breaker Vue Technology, which previously operated as a division of packaging firm MeadWestvaco (NYSE:MWV) before it was spun off as an independent business. Vue's products are aimed at lowering the cost of RFID readers, tags, and software for tracking individual items in a retail setting. Its current customers include electronics retailer Best Buy (NYSE:BBY) and the CVS (NYSE:CVS) pharmacy chain, according to VentureWire.

On Wednesday, privately held EpiCept, which VentureWire says withdrew an IPO filing in May, agreed to acquireMaxim Pharmaceuticals (NASDAQ:MAXM) for roughly $136 million in stock. According to the press release, the merger helps each company diversify. But VentureWire reports that it gives more runway for Maxim's cancer treatment drug, Ceplene, which is vying for acceptance in Europe.

And, finally, this morning VentureWire reported that Amicus Therapeutics received $55 million to develop -- wait for it -- chaperones. It seems the company's therapies help mutant proteins that cause genetic diseases fold into their normal three-dimensional conformation, thereby restoring normal cellular function (hence the friendly moniker). Current trials are focused on treatment for Fabry disease, which causes pain, heart disease, kidney disease, and skin problems. Successful completion could generate demand for therapies aimed at higher-profile genetic ailments.

Once again, there's nothing new to report in public offerings. But, as always, we'll keep looking. See you back here next week.

For more Rule Breaking Foolishness:

  • Want the inside dish on RFID? Fellow Fool Rick Munarriz has it for you.
  • Need a blueprint for biotech profits? We've got one right here.
  • David Gardner holds the secret to Rule Breaker investing. Find out what it is.

Netflix. Marvel. AOL. Starbucks. Find out how David Gardner landed these and other multibaggers by taking a risk-free trial to Motley Fool Rule Breakers today. Your portfolio will thank you.

Fool contributor Tim Beyers oddly never had a chaperone while growing up. Is it too late? Tim owned stock in none of the companies mentioned in this story at the time of publication. You can find out what's in his portfolio by checking Tim's Fool profile, which is here . Best Buy is a Motley Fool Stock Advisor recommendation. The Motley Fool has an ironcladdisclosure policy.